Publications

The BSRBRs have been publishing academic output for nearly fifteen years. Below is a chronological list of the published academic peer reviewed papers from the BSRBRs which are a vital contribution to the evidence base on clinical management and patient safety.


The Registers' systematic collection and analysis of large amounts of patient data traces the effects of biologics drugs in long term use. In addition, a large number of poster and oral presentations have also been given in the UK, Europe and internationally. The majority of these papers are from the RA Register. The  AS register is far younger and its data is still maturing. 


Thousands of people - patients, health professionals, managers, administrators and pharmaceutical sponsors have all contributed to creating this output. BSR is proud to be part of that partnership. 

Most of the papers are available for FREE via open access. A 'DOI' - Digital Object Identifier - has been included to help locate the paper, simply  copy and paste 'DOI' + its number as listed into the URL address bar and tap return. One of the top items will almost certainly link you directly to the paper you want. 

Year of publication


2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003




2017

Risk of lymphoma in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Louise K Mercer, James B Galloway, Mark Lunt, Rebecca Davies, Audrey L S Low, William G Dixon,  Kath D Watson, BSRBR Control Centre Consortium, Deborah P M Symmons, Kimme L Hyrich
Ann Rheum Dis 2017;76:497–503

Pregnancy outcomes in women with rheumatoid arthritis ever treated with rituximab. [LETTER]
Diederik De Cock, Lucy Birmingham, Kath D. Watson, Lianne Kearsley-Fleet, BSRBR Control Centre Consortium, Deborah P. Symmons, Kimme L. Hyrich
Rheumatology (Oxford) 2017 kew493. doi: 10.1093/rheumatology/kew493

Drug specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA.
Jani M, Dixon WG, Kersley-Fleet L, et al. RMD Open 2017;3:e000314. doi:10.1136/rmdopen-2016-000314

Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis.
Mari Kihara, Rebecca Davies, Lianne Kearsley-Fleet, Kath D. Watson, Mark Lunt, Deborah P.M. Symmons, Kimme L. Hyrich on behalf of the British Society for Rheumatology Biologics Register.  Clin Rheumatol (2017) 36:241–250 DOI 10.1007/s10067-016-3485-5

Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis

Audrey SL Low, Deborah P M Symmons, Mark Lunt, Louise K Mercer, Chris P Gale,Kath D Watson, William G Dixon, Kimme L Hyrich, on behalf of the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBRRA) and the BSRBR Control Centre Consortium. Ann Rheum Dis Published Online First: 10 January 2017 doi:10.1136/annrheumdis-2016-209784

 

Back to top




2016

Does sex or ethnicity impact anti-tumour necrosis factor agent use in rheumatoid arthritis?

Elaine M Dennison, Karen A Jameson, Jonathan Marks, Kath Watson, Kimme Hyrich, Deborah Symmons and Cyrus Cooper. [LETTER] Rheumatology (2016) doi: 10.1093/rheumatology/kew466

Factors predicting pain and early discontinuation of tumour necrosis factor-α-inhibitors in people with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register
Daniel F. McWilliams and David A. Walsh BMC Musculoskeletal Disorders  (2016) 17:337  DOI 10.1186/s12891-016-1192-7

The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register
Rheumatoid Arthritis
Lucía Silva-Fernández et al Rheumatology (2016) doi: 10.1093/rheumatology/kew314 First published online: August 22 2016

Effectiveness and safety of TNF inhibitors in adults with juvenile idiopathic arthritis.
Kearsley-Fleet L, McErlane F, Foster HE, et al.
RMD Open 2016;2:e000273. doi:10.1136/rmdopen-2016-000273

Most patients who reach disease remission following anti-TNF therapy continue to report fatigue: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Katie L. Druce et al Rheumatology (2016) doi: 10.1093/rheumatology/kew241 First published online: June 21, 2016

Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers.
Louise K Mercer et al Ann Rheum Dis Published Online First: 15 June 2016 doi:10.1136/annrheumdis-2016-209285

Risk of Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis treated with inhibitors of tumour necrosis factor α: results from BSR's Biologics Register for Rheumatoid Arthritis
Ellen S. Bruce, Lianne Kearsley-Fleet, Kath D. Watson, Deborah P. M. Symmons, and Kimme L. Hyrich [LETTER] Rheumatology published 26 April 2016, 10.1093/rheumatology/kew200

Association between ischaemic stroke and tumor necrosis factor inhibitor therapy in patients with
rheumatoid arthritis
Low ASL et al. Arthritis & Rheumatology accepted article DOI 10.1002/art.39582

        
Back to top

2015

 

The changes in pain which mediate reductions in fatigue likely reflect central not peripheral mechanisms.

Results from the BSRBR-RA Druce KL et al.  Arthritis Care and Research 25 Nov 2015 DOI:10.1002/acr.22803.

The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era.

Morgan C. et al Rheumatology (Oxford) 2015 54 (10) :1780-91. doi: 10.1093/rheumatology/kev105.

 

The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. L Kearsley-Fleet et al

Rheumatology 2015: 54 (6) :1074-1079

The British Society for Rheumatology Biologics Registers in Ankylosing Spondylitis (BSRBR-AS) study: Protocol for a prospective cohort study of the long-term safety and quality of life outcomes of biologics treatment.

GJ Macfarlane et al BMC Musculoskeletal Disorders (2015) 16: 347 DOI 10.1186/s12891-015-0805-x


Determining pathways to improvements in fatigue in Rheumatoid Arthritis - Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

Druce KL et al Arthritis & Rheumatology Vol. 67, No. 9, September 2015, pp 2303–2310 [Epub ahead of print] DOI 10.1002/art.39238

Patients receiving anti-TNF therapies experience clinically important improvements in RA-related fatigue: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. 

Druce K.L. et al Rheumatology (2015) 54 (6): 964-971 DOI:10.1093/rheumatology/keu390

Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

Mercer L. et al Ann Rheum Dis, [Epub ahead of print], DOI:10.1136/annrheumdis-2013-204851 Print ver. 2015; 74:1087–1093 DOI:10.1136/annrheumdis-2013-204851


Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying ant-rheumatic drugs: long-term safety and survival using prospective observational data.

Morgan C.L. et al Rheumatology (Oxford), 53(1), 186-94 DOI: 10.1093/rheumatology/ket333


The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA.

Závada J. et al Ann Rheum Dis, 73(1), 252-255. DOI:10.1136/annrheumdis-2012-203102


A threshold hazard model for estimating serious infection risk following anti-tumor necrosis factor therapy in rheumatoid arthritis patients.

Fu B. et al J Biopharm Stat, 23(2), 461-76 DOI:10.1080/10543406.2011.616973


Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.

Galloway J. et al Ann Rheum Dis, 72(2), 229-234. DOI:10.1136/annrheumdis-2011-201108


Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register. 

McErlane F. et al Rheumatology (Oxford), 52(10), 1905-1913. DOI:10.1093/rheumatology/ket248


Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population.

Mercer L. et al Rheumatology (Oxford), 52(1), 91-98. DOI:10.1093/rheumatology/kes350


Anti-TNF therapy in women with rheumatoid arthritis with a history of carcinoma in situ of the cervix.

Mercer L. et al Ann Rheum Dis, 72(1), 143-144. DOI:10.1136/annrheumdis-2012-201814


The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register.

Mercer L. et al Annals of the rheumatic diseases, 71(6), 869-874. DOI:10.1136/annrheumdis-2011-200622


Effectiveness of Rituximab in Patients with Rheumatoid Arthritis: Observational Study from the British Society for Rheumatology Biologics Register. 

Soliman M. et al J Rheumatol, 39(2), 240-246. DOI:10.3899/jrheum.110610


Rituximab or a second anti-TNF therapy for rheumatoid arthritis patients who have failed their first anti-TNF? Comparative analysis from the British Society for Rheumatology Biologics Register.

Soliman M. et al Arthritis Care Res (Hoboken), 64(8), 1108-1115 DOI:10.1002/acr.21663


Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.

Davies R. et al Ann Rheum Dis, 70(10), 1831-4. DOI:10.1136/ard.2011.153536


The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. 

Galloway JB et al Rheumatology, 50(7), 1341-1342. DOI:10.1093/rheumatology/ker146


Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly.

Galloway J. et al Rheumatology (Oxford), 50(1), 124-131. DOI:10.1093/rheumatology/keq242


Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.

Galloway J. et al Ann Rheum Dis, 70(10), 1810-1814. DOI:10.1136/ard.2011.152769


Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008.

Hyrich K. et al Rheumatology (Oxford), 50(1), 117-123. DOI:10.1093/rheumatology/keq209


Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Soliman M et al Annals of the rheumatic diseases, 70(4), 583-589. DOI:10.1136/ard.2010.139774


Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers.

Strangfeld A. et al Rheumatology (Oxford), 50(1), 146-151. DOI:10.1093/rheumatology/keq301


Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register.

Verstappen S. et al Annals of the rheumatic diseases, 70(5), 823-826. DOI:10.1136/ard.2010.140822


Genome-wide association study of genetic predictors of anti-tumour necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci.

Plant D. et al Arthritis Rheum, 63(3) 645-53 DOI 10.1002/art.30130


Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register.

Dixon W. et al Annals of the Rheumatic Diseases, 69(6), 1086-1091. DOI:10.1136/ard.2009.120626


Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

Dixon W. et al Annals of the Rheumatic Diseases, 69(3), 522. DOI:10.1136/ard.2009.118935


Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for Rheumatology Biologics Register.

Dixon W. et al Arthritis Care Res (Hoboken), 62(6), 755-63. DOI:10.1002/acr.20129


Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis. 

Harrison M. et al Health Qual Life Outcomes, 8(1), 21. DOI:10.1186/1477-7525-8-21


Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. 

Lord P. et al Rheumatology (Oxford), 49(3), 563-567. DOI:10.1093/rheumatology/kep422


No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. 

Lunt M. et al Arthritis and Rheumatism, 62(11), 3145-3153. DOI:10.1002/art.27660


Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. 

Saad A. et al Rheumatology (Oxford), 49(4), 697-705. DOI:10.1093/rheumatology/kep423 CORRECTION Rheumatology (2016) doi: 10.1093/rheumatology/kew454 First published online: December 21, 2016


Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies. 

Saad A. et al Arthritis Care Res (Hoboken), 62(3), 345-53. DOI:10.1002/acr.20104 CORRECTION Rheumatology (2016) doi: 10.1093/rheumatology/kew454 First published online: December 21, 2016


Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register.

Verstappen S. et al Rheumatology, 49(8), 1570-1577. DOI:10.1093/rheumatology/keq131


Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-TNF{alpha} therapy. 

Harrison MJ et al Ann Rheum Dis, 68(2), 209-215. DOI:10.1136/ard.2007.087288


Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity.

Hyrich K. et al Rheumatology (Oxford), 48(10), 1323-7. DOI:10.1093/rheumatology/kep242


Different Methods of Balancing Covariates Leading to Different Effect Estimates in the Presence of Effect Modification.

Lunt M et al American Journal of Epidemiology, 169(7), 909-917. DOI:10.1093/aje/kwn391


Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register.

Saad A.A. et al Arthritis Res Ther, 11(2), R52. DOI:10.1186/ar2670


The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis. 

Harrison M.J. et al Qual Life Res. 18(9) 1195-1205. DOI:10.1007/s11136-009-9539-2


Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug.

Hyrich K.L. et al Rheumatology (Oxford), 47( 7), 1000-5. DOI:10.1093/rheumatology/ken127

 

The British Society for Rheumatology Biologics Register: 6 years on. 

Hyrich K.L. et al Rheumatology (Oxford), 47(10) 1441-3 DOI 10.1093/rheumatology/ken242 


Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.

Brennan A. et al Rheumatology (Oxford), 46( 8), 1345-54. DOI: 10.1093/rheumatology/kem115


Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies.

Dixon W.G. et al Arthritis Rheum, 56( 9), 2896-904. DOI: 10.1002/art.22808


Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. 

Dixon W.G. et al Arthritis Rheum, 56( 9), 2905-12. DOI: 10.1002/art.22809


Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. 

Hyrich K.L. et al Arthritis Rheum, 56( 1), 13-20. DOI:10.1002/art.22331


Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. 

Dixon W.G. et al Arthritis and Rheumatism, 54, 8, 2368-2376. DOI:10.1002/art.21978


Baseline Comorbidity Levels in Biologic and Standard DMARD Treated Patients with Rheumatoid Arthritis: Results from a National Patient Register. 

Hyrich K.L. et al Annals of the Rheumatic Diseases, 65, 7, 895-898. doi:10.1136/ard.2005.043158


Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying anti-rheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register.

Hyrich K.L. et al Arthritis and Rheumatism, 54, 6, 1786-1794. DOI: 10.1002/art.21830 

 

Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: Results from a national population register.

Hyrich K.L. et al Arthritis and Rheumatism, 54, 8, 2701-2702. DOI: 10.1002/art.22028

 

Predictors of response to anti-TNF-{alpha} therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Hyrich K.L. et al Rheumatology, 45, 12, 1558-1565. DOI:10.1093/rheumatology/kel149


UK Consultant Rheumatologists' access to biological agents and views on the BSR Biologics Register. 

Kay L.J. et al Rheumatology (Oxford) 45(11) 1376-9  DOI:10.1093/rheumatology/kel333


The British Society for Rheumatology biologics register. 

Watson K. et al Ann Rheum Dis, 64 Suppl 4, iv42-3. DOI:10.1136/ard.2005.042499


Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.

Hyrich K. et al  Ann Rheum Dis, 63(12), 1538-43. DOI:10.1136/ard.2004.024737


British Society for Rheumatology Biologics Register. 

Silman A. et al Ann Rheum Dis, 62 Suppl 2, ii28-9. DOI:10.1136/ard.62.suppl_2.ii28


The role of the British Society for Rheumatology Biologics Register (BSRBR) and the NICE guidelines for anti-TNF therapy. 

Watson K., Hyrich K. Musculoskeletal Care 2003 1(1) 58-64 DOI:10.1002/msc.39